Novartis AG Share Price London S.E.

Equities

0QM7

CH0038459415

Pharmaceuticals

Market Closed - London S.E. 16:59:30 21/05/2018 BST 5-day change 1st Jan Change
76.86 CHF -1.00% Intraday chart for Novartis AG -0.77% -.--%

Financials

Sales 2024 * 48.96B 44.33B 3,901B Sales 2025 * 50.79B 45.99B 4,047B Capitalization 198B 180B 15,811B
Net income 2024 * 10.29B 9.32B 820B Net income 2025 * 12.05B 10.91B 960B EV / Sales 2024 * 4.32 x
Net Debt 2024 * 12.88B 11.66B 1,026B Net Debt 2025 * 11.28B 10.21B 899B EV / Sales 2025 * 4.13 x
P/E ratio 2024 *
19.3 x
P/E ratio 2025 *
16.5 x
Employees -
Yield 2024 *
3.71%
Yield 2025 *
3.85%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 31/12/04
Director of Finance/CFO 59 31/12/02
Chief Tech/Sci/R&D Officer 62 15/05/22
Members of the board TitleAgeSince
Director/Board Member 62 31/12/12
Director/Board Member 65 27/02/20
Chairman 68 31/12/12
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.24 USD
Average target price
108.4 USD
Spread / Average Target
+11.52%
Consensus